CTI BioPharma Announces Restructuring Plan

Fifty percent reduction in workforce expected to improve efficiencies and preserve capital for pacritinib development SEATTLE, Dec. 13, 2018 -- (Healthcare Sales & Marketing Network) -- CTI BioPharma Corp. (NASDAQ: CTIC) announced today a restructuring... Biopharmaceuticals, Personnel CTI BioPharma, pacritinib, myelofibrosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news